Minerva Neurosciences IPO Info
Company Name: Minerva Neurosciences
Stock Symbol: NERV
Exchange: NASDAQ
Status: Priced
IPO Date: 7/1/2014
IPO Price:
6.00 (
0.33%)
Underwriters
Jefferies LLC
Amount of Offering: N/A
Number of Shares Offered: 5.455 Mil
Shares Outstanding After Offering: N/A
Valuation: N/A
Company Description
Minerva is a clinical-stage biopharmaceutical company focused on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system, or CNS, diseases. Leveraging our domain expertise, we have acquired or in-licensed four development-stage proprietary compounds that we believe have innovative mechanisms of action with potentially positive therapeutic profiles. Our lead product candidates are MIN-101, a compound we are developing for the treatment of patients with schizophrenia, and MIN-117, a compound for the potential treatment of patients suffering from major depressive disorder, or MDD. In addition, our portfolio includes MIN-202, a compound we are co-developing for the treatment of patients suffering from primary and secondary insomnia, and MIN-301, a compound we are developing for the treatment of patients suffering from Parkinson's disease. We believe our innovative product candidates have significant potential to transform the lives of a large number of affected patients and their families who are currently not well-served by available therapies in each of their respective indications.
News Headlines
